Search clinical trials for: tandutinib

Total 6 results

Millennium Pharmaceuticals, Inc.

Withdrawn

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

Acute Myelogenous Leukemia
National Cancer Institute (NCI)

Completed

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Pain | Prostate Cancer | Metastatic Cancer

United States
National Cancer Institute (NCI)

Completed

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor | Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma

United States
Millennium Pharmaceuticals, Inc.

Withdrawn

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Glioblastoma Multiforme

3

Subscribe